You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Locoregional Management of In-Transit Metastasis in Melanoma

Version: N/A ID: GL 8-10 fév 2020
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
F.C. Wright, S. Kellett, A. Sun, T. Hanna, C. Nessim, N.J. Look Hong, C.A. Giacomantonio, C.F. Temple-Oberle, X. Song, T.M. Petrella, and the Melanoma Disease Site Group

Guideline Objective:

To provide guidance on appropriate management of satellite and in-transit metastases from melanoma.

Patient Population:

These recommendations apply to adult patients diagnosed with satellite lesions or in-transit metastases (ITM) from melanoma with or without lymph node metastases. Patients with regional lymph node or distant metastasis were not included.

Intended Guideline Users:

Intended users of this guideline are oncologists specializing in the treatment of patients with melanoma within the province of Ontario. Other intended users include dermatologists, plastic surgeons, otolaryngologists, nuclear medicine doctors, and pathologists.

Research Questions:

  1. What treatments are available for satellite and ITM and what are the response, recurrence, survival, quality of life, and toxicity outcomes associated with each?
  2. What are the recommended treatments for patients with ITM? What is the recommended sequence of treatments?
pdf download Summary (PDF) (192.59 Ko)